Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension.. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension.: Pulmonary Hypertension in Transgenic 5-HTT+ Mice

Archive ouverte

Guignabert, Christophe | Izikki, Mohamed | Tu, Ly Ieng | Li, Zhenlin | Zadigue, Patricia | Barlier-Mur, Anne-Marie | Hanoun, Naïma | Rodman, David | Hamon, Michel | Adnot, Serge | Eddahibi, Saadia

Edité par CCSD ; American Heart Association -

9 pages. International audience. One intrinsic abnormality of pulmonary artery smooth muscle cells (PA-SMCs) in human idiopathic pulmonary hypertension (iPH) is an exaggerated proliferative response to internalized serotonin (5-HT) caused by increased expression of the 5-HT transporter (5-HTT). To investigate whether 5-HTT overexpression in PA-SMCs is sufficient to produce PH, we generated transgenic mice overexpressing 5-HTT under the control of the SM22 promoter. Studies in SM22-LacZ(+) mice showed that the transgene was expressed predominantly in SMCs of pulmonary and systemic vessels. Compared with wild-type mice, SM22-5-HTT(+) mice exhibited a 3- to 4-fold increase in lung 5-HTT mRNA and protein, together with increased lung 5-HT uptake activity, but no changes in platelet 5-HTT activity or blood 5-HT levels. At 8 weeks of age, SM22-5-HTT(+) mice exhibited PH, with marked increases in right ventricular systolic pressure (RVSP), right ventricle/left ventricle+septum ratio, and muscularization of distal pulmonary vessels, but no changes in systemic arterial pressure. PH worsened with age. Except a marked decrease in Kv channels, no changes in the lung expression of mediators of pulmonary vascular remodeling were observed in SM22-5-HTT(+) mice. Compared with wild-type mice, SM22-5-HTT(+) mice showed depressed hypoxic pulmonary vasoconstriction contrasting with greater severity of hypoxia- or monocrotaline-induced PH. These results show that increased 5-HTT expression in PA-SMCs, to a level close to that found in human iPH, lead to PH in mice. They further support a central role for 5-HTT in the pathogenesis of PH, making 5-HTT a potential therapeutic target.

Suggestions

Du même auteur

Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents.. Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents.: FGF2 Inhibition in Pulmonary Hypertension

Archive ouverte | Izikki, Mohamed | CCSD

12 pages. International audience. Pulmonary hypertension (PH) is a progressive, lethal lung disease characterized by pulmonary artery SMC (PA-SMC) hyperplasia leading to right-sided heart failure. Molecular events o...

Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter.. Dichloroacetate treatment partially regresses established pulmonary hypertension in mice with SM22alpha-targeted overexpression of the serotonin transporter.: Efficacy Of DCA Treatment In SM22-5-HTT+ Mice

Archive ouverte | Guignabert, Christophe | CCSD

13 pages; The authors thank Michel Hamon for helpful discussions.. International audience. Voltage-gated potassium (Kv)1.5 is decreased in pulmonary arteries (PAs) of patients with idiopathic pulmonary arterial hype...

Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats.. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats.: 5-HT Transporter Inhibition Prevents PH

Archive ouverte | Guignabert, Christophe | CCSD

9 pages. International audience. BACKGROUND: Progression of pulmonary hypertension (PH) is associated with increased lung expression of the serotonin transporter (5-HTT), which leads to hyperplasia of the pulmonary ...

Chargement des enrichissements...